Health Partners Medicare

PRIOR AUTHORIZATION REQUEST FORM

Taltz - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.		
Patient Name:	Prescriber Name:	
Member Number:	Fax: Phone:	
Date of Birth:	Office Contact:	
_ine of Business: □ Medicare	NPI: State Lic ID:	
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	
REQUEST FOR EXPEDITED REVIEW: By checking this be he life or health of the enrollee or the enrollee's ability to	x and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardi egain maximum function.	ize
Drug Name:		
Strength:		
Directions / SIG:		
Please attach any pertipent medical his	ory including labs and information for this member that may support approval.	
	se answer the following questions and sign.	
Q1. Is the medication prescribed by or in	consultation with a dermatologist or rheumatologist?	
☐ Yes	□ No	
Q2. Is there a confirmation of tuberculos	s (TB) screening results and treatment plan for active or latent infection?	\dashv
Yes	□ No	
O3 Does the natient have a confirmed	agnosis of moderate to severe plaque psoriasis? If No, go to 8.	\dashv
Yes	By No □ No	
		\dashv
Q4. Is the patient 6 to 17 years of age?		
Yes	□ No	
Q5. Is there documentation of an inaded	uate response, intolerance or contraindication to Enbrel?	
☐ Yes	□ No	
Q6. Is the patient 18 years of age or old		\dashv
☐ Yes	□ No	
		\dashv
	uate response, intolerance or contraindication to Humira, Enbrel OR Skyrizi?	
Yes	□ No	
Q8. Does the patient have a confirmed of	agnosis of active psoriatic arthritis? If No, go to 11.	
Yes	□ No	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Health Partners •••• Medicare

PRIOR AUTHORIZATION REQUEST FORM

Taltz - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:			
Q9. Is the patient 18 years of age or older?				
☐ Yes	□ No			
Q10. Is there documentation of inadequate response, intolerance or contraindication to Enbrel, Humira OR Xeljanz/Xeljanz XR?				
☐ Yes	□ No			
Q11. Does the patient have a confirmed diagnosis of active ankylosing spondylitis (AS)?If No, go to 14.				
☐ Yes	□ No			
Q12. Is the patient 18 years of age or older?				
☐ Yes	□No			
Q13. Is there documentation of inadequate response, intolerance or contraindication to Humira OR Enbrel?				
☐ Yes	□ No			
Q14. Does the patient have a confirmed diagnosis of non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation?				
☐ Yes	□No			
Q15. Is the patient 18 years of age or older?				
☐ Yes	□No			
Q16. Is there documentation of inadequate response, intolerance or contraindication to Humira?				
☐ Yes	□ No			
Q17. Additional Information:				
Q18. Duration:				
☐ 12 months	☐ Other			
Prescriber Signature	Date			
	2023 Medicare Prior Authorization Request			

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document